Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Vaccine development and manufacturing / / edited by Emily P. Wen, Ronald Ellis, Narahari S. Pujar ; Michel Chartrain [and thirty one others], contributors
| Vaccine development and manufacturing / / edited by Emily P. Wen, Ronald Ellis, Narahari S. Pujar ; Michel Chartrain [and thirty one others], contributors |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2015 |
| Descrizione fisica | 1 online resource (1044 p.) |
| Disciplina | 615.3/72 |
| Collana | Wiley Series in Biotechnology and Bioengineering |
| Soggetto topico | Vaccines |
| ISBN |
1-78684-221-1
1-118-87090-5 1-118-87091-3 1-118-87092-1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Series; Title Page; Copyright; Acknowledgments; Preface; Contributors; Chapter 1: History of Vaccine Process Development; 1.1 Introduction; 1.2 Vaccines Bioprocess Evolution; 1.3 Live Attenuated and Inactivated Virus Vaccines; 1.4 Live or Whole-Killed Bacterial Vaccines; 1.5 Classical Subunit Vaccines; 1.6 Recombinant Subunit Vaccines; 1.7 Conjugate Vaccines; 1.8 Downstream Processing; 1.9 Vaccines for the Developing World: Large Volume, Low Cost, and Thermostable; 1.10 Summary; Acknowledgments; References
Chapter 2: The Production of Plasmid DNA Vaccine in Escherichia coli: A Novel Bacterial-Based Vaccine Production Platform2.1 Introduction: E. coli in Vaccine Production; 2.2 Brief Overview of DNA Vaccines: Mechanisms and Methods of Vaccinations; 2.3 Current Status of DNA Vaccines; 2.4 Required Physical Properties of Plasmid DNA Vaccines; 2.5 Choice of E. coli Host Strain; 2.6 Factors Influencing Plasmid Stability; 2.7 Transformation, Selection of Producing Clones, and Cell Banking; 2.8 Production Process; 2.9 Requirements for Clinical Supplies; 2.10 Conclusions; References Chapter 3: Fungal Expression Systems for Vaccine Production3.1 Introduction; 3.2 Hepatitis B Vaccines; 3.3 Human Papillomavirus Vaccine; 3.4 Malaria Vaccine Candidates; 3.5 HIV Vaccine Candidates; 3.6 Veterinary Vaccines; 3.7 Perspectives; 3.8 Concluding Remarks; Acknowledgments; References; Chapter 4: Novel Expression Systems for Vaccine Production; 4.1 Introduction; 4.2 Subunit Vaccines; 4.3 Expression Systems; 4.4 Novel Expression Systems; 4.5 Production of Recombinant Proteins in Plants; 4.6 Launch Vector System; 4.7 Conclusions; References; Chapter 5: Viral Vaccines Purification 5.1 Introduction5.2 Process Tasks; 5.3 Conclusions and Outlook; Acknowledgments; Nomenclature; Abbreviations; References; Chapter 6: Protein Subunit Vaccine Purification; 6.1 Introduction; 6.2 Purification Technologies-Applications in Protein Subunit Vaccine Purification; 6.3 Purification Process Development and Scale-Up for Protein Subunit Vaccine; 6.4 Process Definition Studies; 6.5 Process Economy and Automation; 6.6 Application of Process Analytical Technology in Protein Purification; 6.7 Downstream Purification-An Outlook; References; Chapter 7: Conjugate Vaccine Production Technology 7.1 Conjugate Vaccine Production Technology7.2 Preparation of Antigen and Carrier Protein; 7.3 Polysaccharide Size; 7.4 Activation and Coupling of Polysaccharide and Carrier Protein; 7.5 Characterization of the Conjugate; 7.6 Future Directions; References; Chapter 8: Stabilization and Formulation of Vaccines; 8.1 Introduction; 8.2 An Example of a Modern Vaccine Characterization Strategy; 8.3 A Comprehensive Approach to Vaccine Formulation in Practice; 8.4 Conclusions; References; Chapter 9: Lyophilization In Vaccine Processes; 9.1 Introduction; 9.2 Formulation; 9.3 Filling; 9.4 Lyophilization 9.5 Equipment |
| Record Nr. | UNINA-9910140501703321 |
| Hoboken, New Jersey : , : Wiley, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Vaccine development and manufacturing / / edited by Emily P. Wen, Ronald Ellis, Narahari S. Pujar ; Michel Chartrain [and thirty one others], contributors
| Vaccine development and manufacturing / / edited by Emily P. Wen, Ronald Ellis, Narahari S. Pujar ; Michel Chartrain [and thirty one others], contributors |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2015 |
| Descrizione fisica | 1 online resource (1044 p.) |
| Disciplina | 615.3/72 |
| Collana | Wiley Series in Biotechnology and Bioengineering |
| Soggetto topico | Vaccines |
| ISBN |
1-78684-221-1
1-118-87090-5 1-118-87091-3 1-118-87092-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Series; Title Page; Copyright; Acknowledgments; Preface; Contributors; Chapter 1: History of Vaccine Process Development; 1.1 Introduction; 1.2 Vaccines Bioprocess Evolution; 1.3 Live Attenuated and Inactivated Virus Vaccines; 1.4 Live or Whole-Killed Bacterial Vaccines; 1.5 Classical Subunit Vaccines; 1.6 Recombinant Subunit Vaccines; 1.7 Conjugate Vaccines; 1.8 Downstream Processing; 1.9 Vaccines for the Developing World: Large Volume, Low Cost, and Thermostable; 1.10 Summary; Acknowledgments; References
Chapter 2: The Production of Plasmid DNA Vaccine in Escherichia coli: A Novel Bacterial-Based Vaccine Production Platform2.1 Introduction: E. coli in Vaccine Production; 2.2 Brief Overview of DNA Vaccines: Mechanisms and Methods of Vaccinations; 2.3 Current Status of DNA Vaccines; 2.4 Required Physical Properties of Plasmid DNA Vaccines; 2.5 Choice of E. coli Host Strain; 2.6 Factors Influencing Plasmid Stability; 2.7 Transformation, Selection of Producing Clones, and Cell Banking; 2.8 Production Process; 2.9 Requirements for Clinical Supplies; 2.10 Conclusions; References Chapter 3: Fungal Expression Systems for Vaccine Production3.1 Introduction; 3.2 Hepatitis B Vaccines; 3.3 Human Papillomavirus Vaccine; 3.4 Malaria Vaccine Candidates; 3.5 HIV Vaccine Candidates; 3.6 Veterinary Vaccines; 3.7 Perspectives; 3.8 Concluding Remarks; Acknowledgments; References; Chapter 4: Novel Expression Systems for Vaccine Production; 4.1 Introduction; 4.2 Subunit Vaccines; 4.3 Expression Systems; 4.4 Novel Expression Systems; 4.5 Production of Recombinant Proteins in Plants; 4.6 Launch Vector System; 4.7 Conclusions; References; Chapter 5: Viral Vaccines Purification 5.1 Introduction5.2 Process Tasks; 5.3 Conclusions and Outlook; Acknowledgments; Nomenclature; Abbreviations; References; Chapter 6: Protein Subunit Vaccine Purification; 6.1 Introduction; 6.2 Purification Technologies-Applications in Protein Subunit Vaccine Purification; 6.3 Purification Process Development and Scale-Up for Protein Subunit Vaccine; 6.4 Process Definition Studies; 6.5 Process Economy and Automation; 6.6 Application of Process Analytical Technology in Protein Purification; 6.7 Downstream Purification-An Outlook; References; Chapter 7: Conjugate Vaccine Production Technology 7.1 Conjugate Vaccine Production Technology7.2 Preparation of Antigen and Carrier Protein; 7.3 Polysaccharide Size; 7.4 Activation and Coupling of Polysaccharide and Carrier Protein; 7.5 Characterization of the Conjugate; 7.6 Future Directions; References; Chapter 8: Stabilization and Formulation of Vaccines; 8.1 Introduction; 8.2 An Example of a Modern Vaccine Characterization Strategy; 8.3 A Comprehensive Approach to Vaccine Formulation in Practice; 8.4 Conclusions; References; Chapter 9: Lyophilization In Vaccine Processes; 9.1 Introduction; 9.2 Formulation; 9.3 Filling; 9.4 Lyophilization 9.5 Equipment |
| Record Nr. | UNINA-9910815553103321 |
| Hoboken, New Jersey : , : Wiley, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||